



MONTHLY PROGRESS REPORT

Name of CSE Issuer: LeenLife Pharma International Inc. (the "Issuer").

Trading Symbol: LLP

Number of Outstanding Listed Securities: 34,015,318

Date: Month of May 2017

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Company has been developing sales orders for the inclusion of its omega products in the production of bread, cheese, meat and noodles.

The Issuer plans to bring its proprietary omega fatty acid products to Canada and the United States. The Issuer has developed technology to combine omega fatty acids into various food products such as bread, cheese, noodles, milk, juices and chocolate. The Company has achieved marginal sales recently.

2. Provide a general overview and discussion of the activities of management.

The Company previously entered into an agreement with LeenLife Pharma S.A., a company incorporated under the laws of Poland ("LeenLife SA") and its shareholders/management (the "Vendors") whereby the Company issued 12,232,788 common shares (the "Acquisition Shares") in the names of the Vendors, but that such shares were held back and not delivered until the Company was satisfied that it was provided effective control of LeenLife SA including pertinent information in exchange for 90% control of this company (the "Transaction").

Due to the failure of the Vendors and the management of LeenLife SA in Poland satisfying the essence of the Transaction by delivering control of this Polish company with operating documents to the Company, and having refused to co-operate with the Company with such matters as allowing an audit of the records of this Polish company by a major international audit firm engaged by the Company, having offices in Canada and Poland, as required to satisfy the Company's regulatory requirements, the Transaction has been repudiated by the actions of the Vendors. As the transaction has been repudiated, a liability which would have been created from the receipt of the shares from the Company to the Vendors causing a tax liability of \$563,044 is no longer applicable. This amount was written off in previous financial statements.

The Company returned to treasury and cancelled the Acquisition Shares and returned the original LeenLife SA shares. With the return to treasury and cancellation of these 12,232,788 common shares the Company now has a total of 34,015,318 issued and outstanding common shares.

Further to this matter, on the basis of funds advanced by the Company to LeenLife SA and its suppliers, as provided for by the laws in Poland, the Company has been issued additional shares of LeenLife SA, in the name of the Company and changed the chairperson to gain control of LeenLife SA. The Company has received court approval in Poland for the actions taken by the Company and awarded control of LeenLife SA by endorsing share issuances, the appointment of the new chairperson and dismissed all claims by the Vendors.

The Company is currently customizing the technology for entry into the markets of Canada and the United States. This will provide the Company with proprietary technology and lower the cost of production. The Company has been focussed on Poland and is preparing for entry to Canada and the United States. According to various marketing reports 50% of future world sales of omega products will be in North America, and 25% in Europe.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Not applicable.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Not applicable.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Not applicable.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Not applicable (other than as disclosed in Section 2 above).

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Not applicable.

8. Describe the acquisition of new customers or loss of customers.
- Not applicable.**
9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.
- Not applicable (other than as disclosed in Section 2 above).**
10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.
- Not applicable.**
11. Report on any labour disputes and resolutions of those disputes if applicable.
- Not applicable.**
12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.
- Not applicable.**
13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.
- Not applicable.**
14. Provide details of any securities issued and options or warrants granted.
- Not applicable.**
15. Provide details of any loans to or by Related Persons.
- Not applicable.**
16. Provide details of any changes in directors, officers or committee members.
- Not applicable.**
17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The Company's primary source of funding is through the issuance of share capital. When the capital markets are depressed, the Company's activity level normally declines accordingly. As capital markets strengthen and the Company is able to secure equity financing with favorable terms, the Company's activity levels and the size and scope of planned projects will typically increase.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated June 28, 2017.

Casey Forward

Name of Director or Senior Officer

/s/ Casey Forward

Signature

Director

Official Capacity

Issuer Details <i>Name of Issuer</i> LeenLife Pharma International Inc.	<i>For Month End</i> May 2017	<i>Date of Report</i> <i>YY/MM/DD</i> 17/06/28
<i>Issuer Address</i> Suite 380 – 580 Hornby Street		
<i>City/Province/Postal Code</i> Vancouver, BC, V6C 3B6	<i>Issuer Fax No.</i>	<i>Issuer Telephone No.</i> (778) 688-1799
<i>Contact Name</i> Casey Forward	<i>Contact Position</i> Director	<i>Contact Telephone No.</i> (778) 688-1799
<i>Contact Email Address</i> casey@caseyforward.com	<i>Web Site Address</i> www.leenlifepharma.com	